drugset / Trial / NCT01511302

Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma

NCT01511302

Phase 1 Completed 65 enrolled Revalesio Corporation
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether RNS60, in combination with budesonide, is safe in mild to moderate asthmatics when taken by nebulization over a 28-day period, compared to a 28-day control period.

Timeline

Start
2012-06
Primary completion
2013-04
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 0.25 mg Other
Subject Budesonide Small molecule 0.5 mg Other
Subject RNS60 Other / unclassified 2 ml Other

Indications